Akari Therapeutics, Plc
AKTX
$0.33
-$0.01-1.82%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 10.19M | 9.92M | 9.71M | 10.71M | 10.24M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.16M | 12.79M | 15.23M | 17.69M | 18.49M |
| Operating Income | -13.16M | -12.79M | -15.23M | -17.69M | -18.49M |
| Income Before Tax | -16.86M | -12.27M | -17.93M | -19.79M | -20.16M |
| Income Tax Expenses | -1.09M | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.77 | -12.27 | -17.93 | -19.79 | -20.16 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.77M | -12.27M | -17.93M | -19.79M | -20.16M |
| EBIT | -13.16M | -12.79M | -15.23M | -17.69M | -18.49M |
| EBITDA | -13.15M | -12.78M | -15.22M | -17.68M | -18.47M |
| EPS Basic | -1.17K | -1.26K | -2.74K | -4.12K | -5.62K |
| Normalized Basic EPS | -0.26 | -0.33 | -0.65 | -1.08 | -1.57 |
| EPS Diluted | -1.17K | -1.26K | -2.74K | -4.12K | -5.62K |
| Normalized Diluted EPS | -0.26 | -0.33 | -0.65 | -1.08 | -1.57 |
| Average Basic Shares Outstanding | 110.84M | 90.37M | 68.31M | 47.75M | 32.74M |
| Average Diluted Shares Outstanding | 55.30K | 45.00K | 34.00K | 23.70K | 16.10K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |